Allen Institute for Artificial Intelligence
supp.ai logo
supp.ai

Discover Supplement-Drug Interactions

Disclaimer: The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The tool is not a substitute for the care provided… (more)
Last Updated: 3 years ago

Possible Interaction: Catechin and Ng-Nitroarginine Methyl Ester

Research Papers that Mention the Interaction

Pretreatment … with Nω-nitro-l-arginine methylester (L-NAME, an inhibitor of nitric oxide synthase) or 1H-[1,2,4] oxadiazolo[4,3-a]quinoxalin-… (ODQ, an inhibitor of soluble guanylate cyclase), resulted in a significant change of relaxant effect induced by catechin , and a slight … cryptostrobin-induced relaxation.
Pharmacological reports : PR  •  2019  |  View Paper
Mechanical removal of endothelium, blockade of soluble guanylyl cyclase by 1H-1,2,4-… (ODQ, 1 and 5 microM) or inhibition of nitric oxide (NO) synthase by N(G)-nitro-L-arginine (L-NAME, 50 … response to catechin ; moreover, the NO donor S-nitroso-… the vasorelaxant responses to EGCG.
European journal of pharmacology  •  2009  |  View Paper
N(G)-nitro-L-arginine methyl ester (10(-5) M) enhanced the contractile responses in the PA rings from both C and HLU animals and completely abolished the differential responses to PE and U4 in HLU vs. C animals.
Journal of applied physiology  •  2002  |  View Paper
L-NAME enhanced Fmax of AngII contractions by about 75% in C, 120% in I1, and 74% in I2 groups; accordingly, it augmented the final steady-state force in C and I1 but not in I2.
Similarly, L-NAME increased Fmax (30-40%) of AVP and ET1 contractions in C and I1 groups but failed to do so in contractions of I2 group.
Canadian journal of physiology and pharmacology  •  1998  |  View Paper
A supramaximal dose of L-NAME (10 mg/kg body wt) increased sBP in C and D rats to a similar degree.
Diabetes  •  1994  |  View Paper